Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
Part of paid clinical trials in San Francisco, California.
- Sponsor
- Power Life Sciences Inc.
- Study ID
- NCT06070272
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Recurrent Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
Clinical studies, with a dedicated focus on recurrent prostate cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications outperform traditional therapies, providing substantial evidence to endorse their broader utilization. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with recurrent prostate cancer.
Key Dates
- Start date
- Oct 31, 2024
- Status verified
- Sep 2023
- Primary completion
- Oct 31, 2025
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 500 participants (estimated)
Primary Outcome Measure
Number of patients who decide to participate in a recurrent prostate cancer clinical research [ Time Frame: 3 months ]
Central Contacts
- Michael B Gill4159004227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Power Life Sciences | San Francisco | California | 94107 |
Find similar trials in San Francisco, CA
Related Studies
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPHASE2/PHASE3 · Recruiting · VA Office of Research and Development · Long Beach, California
- Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 SystemPHASE1/PHASE2 · Recruiting · SpectraCure AB · New York, New York
- PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test ScoresPHASE2/PHASE3 · Recruiting · H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida
- Tumor Microenvironment Analysis of Prostate Cancer MetastasisRecruiting · Columbia University · New York, New York